The Paper reporter Yang Yang

  On November 29, after the expiry of the national organization's centralized procurement agreement for coronary stents, bids for continued procurement were opened in Changzhou, Jiangsu, resulting in the proposed selection results.

A total of 14 products from 10 companies have been qualified for the selection, and the average price of the selected stents is about 770 yuan. It is expected that patients will use the selected products purchased continuously in January 2023.

  According to the National Medical Insurance Administration, this continuation procurement is the first exploration to carry out the continuation work nationwide. A total of 3696 medical institutions participated, an increase of 1288 compared with the first batch of centralized procurement. A total of 1.865 million medical institutions reported the demand, which is the first batch 1.7 times that of centralized mining.

Compared with the previous round of centralized procurement, the number of medical institutions participating in this continuous procurement has increased by 40%, the purchase volume of stents has increased by 30%, the number of selected enterprises has increased by 2, and the number of selected products has increased by 4.

  The average price of the selected brackets for this continuous purchase is about 770 yuan, plus the accompanying service fee, the terminal price range is 730 yuan to 848 yuan.

There are 14 products to be selected in this continuous procurement, involving a total of 10 domestic and foreign enterprises such as Medtronic and Shanghai MicroPort, and the selection rate of enterprises reached 91%.

  Prior to that, on November 9, the National Organization of High-value Medical Consumables Joint Procurement Office (hereinafter referred to as "Joint Procurement Office") issued the "National Organization's Continuing Procurement Announcement after the Expiration of the Centralized Procurement Agreement for Coronary Stents (No. 2)", stating that the national The centralized procurement agreement for tissue coronary stents will expire in January 2023.

At that time, all provinces (autonomous regions, municipalities directly under the Central Government) and the Xinjiang Production and Construction Corps will form a procurement alliance, and representatives will be appointed to form a joint procurement office to carry out centralized procurement of high-value medical consumables. The Tianjin Pharmaceutical Procurement Center will undertake the daily work and implement it.

  The bidding for the first batch of high-value medical consumables was opened in Tianjin on November 5, 2020, and implementation began in January 2021. 10 products were selected, and the price of the stent dropped from an average price of about 13,000 yuan to about 700 yuan, a year-on-year decrease of more than 100,000 yuan. 90%.

As of the end of October 2022, a total of 3.2 million selected brackets have been purchased, which is 1.3 times the agreed purchase volume.

  At present, the National Medical Insurance Bureau has launched 7 batches of centralized procurement of drugs, 3 batches of high-value medical consumables, and more than 100 batches of provincial centralized procurement.

This continued procurement of coronary stents is the first contract renewal for the national centralized procurement of high-value consumables. Adhering to the principle of "capacity" and focusing on stabilizing prices, supply, and expectations, the procurement rules applicable to the continuation of the centralized procurement agreement after expiration .

  The National Medical Insurance Bureau stated that in the next step, it will work with relevant departments to guide the joint procurement and various regions to complete the selection results such as the signing of procurement agreements, the listing of selected products, and the prepayment of medical insurance funds in accordance with the existing regulations for the national organization of centralized procurement of high-value medical consumables. The implementation work will ensure that patients across the country will use the selected products purchased continuously in January 2023, which will be smoothly connected with the previous procurement cycle.